How to give FCM for Iron deficiency anemia
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information to provide a detailed, well-sourced answer.
Ferric Carboxymaltose (FCM) for Iron Deficiency Anemia
What is FCM?
Ferric carboxymaltose (brand name: Injectafer) is a third-generation IV iron preparation consisting of a ferric hydroxide core with a carbohydrate shell. It allows high-dose iron repletion in a single rapid infusion — up to 1000 mg in 15 minutes — making it highly convenient compared to older agents.
— Goodman & Gilman's The Pharmacological Basis of Therapeutics
Indications
FCM is FDA-approved for iron deficiency anemia in adults. Key indications include:
- Intolerance to oral iron
- Malabsorption (sprue, short-bowel syndrome)
- Non-adherence to oral therapy
- Chronic blood loss (GI, menstrual)
- Patients receiving erythropoietin (ESA) therapy
- CKD patients (especially on hemodialysis)
- Post-bariatric surgery
IV iron can create iron stores in 1–2 sessions, something oral iron would take months to achieve.
— Goodman & Gilman's
Dosing
| Patient Weight | Dose | Schedule |
|---|---|---|
| ≥ 50 kg | 750 mg per dose × 2 doses | At least 7 days apart |
| < 50 kg | 15 mg/kg per dose × 2 doses | At least 7 days apart |
| FDA 2021 update | Single 1000 mg dose | — |
Maximum single dose: 750 mg (standard) or 1000 mg (newer FDA approval)
Maximum course: 1500 mg per course
— Goodman & Gilman's; National Kidney Foundation Primer on Kidney Diseases 8e
Total Iron Dose Estimation (Ganzoni Formula)
Use this formula to estimate the total iron deficit before therapy:
Total iron dose (mg) = [Actual body weight (kg) × (Target Hb − Actual Hb) × 2.4] + Iron stores (500 mg)
- Target Hb is typically 13–15 g/dL for adults
- Iron stores replacement = 500 mg (standard)
— Washington Manual of Medical Therapeutics
How to Administer
| Route | Details |
|---|---|
| Intravenous infusion | Dilute in 0.9% NaCl; infuse over ≥ 15 minutes |
| IV push (undiluted) | Up to 200 mg over at least 10 minutes (for smaller doses) |
| No test dose required | Unlike iron dextran |
Key points:
- No premedication required in most patients
- Observe patient for at least 30 minutes post-infusion for hypersensitivity reactions
- Do not give with active infection/fever (risk of sepsis and adverse reactions)
Pharmacokinetics
- Rapidly cleared from circulation after IV administration
- ~80% distributed to bone marrow, with remainder going to liver and spleen
- Leads to transient rise in serum iron, ferritin, and TSAT → followed by correction in Hb levels
Adverse Effects
| Common | Serious/Rare |
|---|---|
| Headache, dizziness | Hypersensitivity / anaphylactoid reaction |
| Nausea, abdominal pain | Severe hypotension (especially with rapid injection) |
| Constipation, diarrhea | Hypophosphatemia ⚠️ (a distinctive side effect of FCM) |
| Rash, injection site reactions | — |
The incidence of drug-related adverse events is similar to that of oral ferrous sulfate.
FCM (and ferric derisomaltose) can be associated with significant hypophosphatemia — monitor phosphate levels, especially in patients already at risk.
— Goodman & Gilman's; Washington Manual of Medical Therapeutics
Contraindications & Precautions
- Active infection / fever — defer infusion
- Iron overload states (hemochromatosis, hemosiderosis)
- Withhold if plasma ferritin > 800 μg/L
- MRI considerations: Wait at least 1 week after IV iron sucrose/gluconate before MRI; FCM can also transiently alter MRI signal
Comparison with Other IV Iron Agents
| Agent | Generation | Max Single Dose | Test Dose? | Notable |
|---|---|---|---|---|
| Iron dextran | 1st | 1000 mg | ✅ Required | High anaphylaxis risk |
| Ferric gluconate | 2nd | 125–250 mg | ❌ Not needed | Multiple doses needed |
| Iron sucrose | 2nd | 100–300 mg | ❌ Not needed | Multiple doses needed |
| Ferric carboxymaltose | 3rd | 750–1000 mg | ❌ Not needed | Rapid; hypophosphatemia risk |
| Ferumoxytol | 3rd | 1020 mg | ❌ Not needed | Interferes with MRI |
| Iron isomaltoside | 3rd | 1000–1500 mg | ❌ Not needed | Single-dose convenience |
— Goodman & Gilman's; Washington Manual of Medical Therapeutics
Monitoring After FCM
- CBC and reticulocyte count: 2–4 weeks post-infusion
- Serum ferritin + TSAT: at 4–8 weeks
- Serum phosphate: especially with repeated dosing (FCM-induced hypophosphatemia)
- Expect Hb rise within 1–2 weeks; full response in 4–8 weeks
Help me diagnose
Asking for Preferences
Please share the clinical case — include as much detail as you have:
- Patient demographics (age, sex)
- Chief complaint & history (symptoms, onset, duration, progression)
- Past medical/surgical history, medications, family history
- Examination findings
- Investigations (labs, imaging, ECG, etc.) if available
The more detail you provide, the more accurate and useful the differential will be.
35 year old female, Indian origin, PIP joint and fingers swelling and pain, tenderness present
Asking for Preferences
Reading File
Finding Sources
Finding Sources
35 year old female, Indian origin, PIP joint and fingers swelling and pain, tenderness present
35 year old female, Indian origin, PIP joint and fingers swelling and pain, tenderness present
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Excellent — this is a rich section. I have all I need for a thorough differential diagnosis and workup.
Differential Diagnosis
35-year-old Indian female | PIP joint swelling, pain, tenderness (bilateral fingers)
Most Likely Diagnosis: Rheumatoid Arthritis (RA)
This presentation is classic for RA:
- Female, peak age 20–50 years — RA affects women 3:1 over men
- PIP and MCP joint involvement — hallmark small joint distribution
- Symmetric synovitis — the defining feature of RA
- Indian subcontinent populations have a similar 1–2% prevalence
ACR 1987 Classification Criteria for RA (≥4 of 7 = RA)
| # | Criterion | Definition |
|---|---|---|
| 1 | Morning stiffness | ≥1 hour before maximal improvement |
| 2 | Arthritis of ≥3 joint areas | PIP, MCP, wrist, elbow, knee, ankle, MTP |
| 3 | Arthritis of hand joints | Wrist, MCP, or PIP involvement |
| 4 | Symmetric arthritis | Same joint areas bilaterally |
| 5 | Rheumatoid nodules | Over bony prominences or extensor surfaces |
| 6 | Serum RF positive | — |
| 7 | Radiographic changes | Erosions or periarticular osteopenia on hand X-ray |
Symptoms must be present for ≥6 weeks for diagnosis. Radiographic erosions appear only several months to 1 year after onset.
— Textbook of Family Medicine 9e
Other Differentials to Consider
2. Systemic Lupus Erythematosus (SLE)
- Common in young Indian women (higher prevalence in South Asian females)
- Arthritis/arthralgia in small joints — can mimic RA
- Key distinguishing features: butterfly malar rash, photosensitivity, serositis, renal involvement, oral ulcers
- ANA positive; anti-dsDNA elevated; complement (C3/C4) low
- Jaccoud arthropathy — non-erosive, deforming
3. Psoriatic Arthritis
- PIP involvement common; can be asymmetric
- Look for psoriatic skin/nail changes (pitting, onycholysis)
- "Sausage digits" (dactylitis) are characteristic
- RF negative; HLA-B27 may be positive
4. Reactive Arthritis
- Follows GI or genitourinary infection
- Asymmetric oligoarthritis; may have urethritis, conjunctivitis (Reiter's triad)
- Ask about recent infection history
5. Osteoarthritis (OA)
- PIP involvement = Bouchard's nodes (hard, bony swelling)
- Less likely at age 35 unless post-traumatic or secondary
- Morning stiffness < 30 minutes; no systemic features
6. Viral Arthritis
- Chikungunya, Parvovirus B19, Hepatitis B/C — all common in India
- Acute onset, symmetric small joint polyarthritis
- Usually self-limiting; RF may be transiently positive
- Chikungunya especially prevalent in Indian subcontinent — can cause severe, symmetric PIP/MCP arthritis
7. Undifferentiated Connective Tissue Disease (UCTD)
- Features of connective tissue disease that don't yet fulfill criteria for a specific diagnosis
- ANA positive but incomplete criteria for SLE/RA/SSc
Recommended Workup
Blood Tests
| Investigation | Purpose |
|---|---|
| RF (Rheumatoid Factor) | Positive in ~70–80% RA; not specific |
| Anti-CCP antibodies | Highly specific for RA (~95%); positive earlier than RF |
| ANA | Screen for SLE/UCTD |
| Anti-dsDNA, Anti-Sm | If ANA positive (SLE workup) |
| CBC | Anemia of chronic disease in RA; leukopenia in SLE |
| ESR / CRP | Disease activity markers |
| Serum uric acid | Rule out gout (less common in small joints/females) |
| LFT, RFT | Baseline before DMARDs |
| Chikungunya / Parvovirus serology | If acute onset, travel/exposure history |
| HBsAg, anti-HCV | If viral arthritis suspected |
Imaging
| Purpose | |
|---|---|
| X-ray both hands (PA view) | Periarticular osteopenia, joint space narrowing, erosions |
| Ultrasound of PIP/MCP joints | Detects synovitis earlier than X-ray |
| MRI hands | Most sensitive for early erosions |
Red Flag Features to Elicit
Ask specifically about:
- Morning stiffness duration (>1 hr → inflammatory)
- Bilateral symmetric involvement (wrists, MCPs)
- Systemic symptoms: fatigue, fever, weight loss
- Skin: rash, psoriasis, photosensitivity
- Eye: redness, dryness (Sjögren's / reactive)
- Family history of autoimmune disease
- Recent infection (preceding the joint symptoms)
- Oral contraceptive/pregnancy history (SLE trigger)
Summary
| Diagnosis | Favors | Against |
|---|---|---|
| RA | Young female, symmetric PIP/finger arthritis | Need to confirm ≥6 wks, RF/anti-CCP |
| SLE | Indian female, small joint arthritis | Need systemic features, ANA |
| Chikungunya | Indian origin, acute onset | Need serology, usually self-limiting |
| Psoriatic arthritis | PIP involvement | No skin/nail changes mentioned |
| Viral arthritis | Acute presentation | Need serology |
Next step: Check anti-CCP and RF, ANA, CRP/ESR, and X-ray both hands. Anti-CCP positivity in this clinical picture would strongly support early RA and guide initiation of DMARDs early to prevent joint destruction.
This is a shared conversation. Sign in to Orris to start your own chat.